S
SPARK
Biotechnology company developing novel small-molecule therapeutics through advanced drug discovery platforms targeting cancer, neurological, and metabolic diseases.
About SPARK
SPARK Biopharma, founded by Dr. Seung Bum Park in 2016, focuses on the discovery and development of small molecule therapeutics aimed at modulating the tumor microenvironment (TME) in the field of immune oncology. The company collaborates with the CRI Center for Chemical Proteomics at Seoul National University and other scientific partners to advance its drug discovery programs. SPARK Biopharma leverages proprietary technology platforms such as pDOS, Seoul Fluor, and FITGE to identify and develop novel therapeutic agents. The business primarily serves the pharmaceutical and biotechnology sectors, targeting clients interested in innovative cancer treatments. SPARK Biopharma operates within the competitive landscape of oncology drug development, generating revenue through partnerships and potential licensing agreements for its clinical candidates. The company's business model is centered around research and development, with a focus on delivering effective and targeted cancer therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Seoul, South Korea
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 71.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Molecular Biology, Molecular, Precision Medicine, Spinout, Clinical Trials, Small Molecules, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2026 | $26M | $106M | Korea Development Bank · SJG Partners · Shinhan Capital · Industrial Bank of Korea | ↗ |
| SERIES COther financing | Apr 2022 | $21M | $84M | IMM Investment · Company K Partners · We Ventures · Shinhan Venture Investment | ↗ |
Growth signals
Latest recorded traffic for SPARK is 1.1K monthly website visits, up 107.5% over the last three months. SPARK's team declined 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Korea Tech Incubator Program For Startup
Series A3 investors entered at this stage
Company K Partners
Solidus Investment
KB Investment
Series B and later16 investors entered at this stage
IMM Investment
We Ventures
Shinhan Venture Investment- KIKiwoom Investment
Medytox Venture Investment- TMTimefolio Asset Management
- DIDTN Investment
- DSDAOL Investment & Securities
Korea Development Bank- SPSJG Partners
- SCShinhan Capital
Industrial Bank of Korea
Openwater Investment- EPEmford Equity Partners
- APAOA Capital Partners
Plexus Partners
Other known investors1 additional known investor
Seoul National University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SPARK on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SPARK’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.